Notified bodies play a significant role in helping medical device manufacturers bring new products to the EU market. Their primary responsibility is to conduct conformity assessments and grant CE certificates for devices. This involves auditing the manufacturer’s quality management system (QMS) and reviewing the technical documentation for the different classes of devices.
To issue CE certificates, notified bodies must be recertified and designated according to the new MDR. The goal is to identify the notified bodies that are truly qualified to ensure the safety and effectiveness of the products that they are evaluating. Starting on November 26, 2017, notified bodies were able to submit applications to become designated under the MDR. A complete listing of the notified bodies that are officially designated is maintained on the NANDO (New Approach Notified and Designated Organizations) database.
Under the MDR, notified bodies will take on more responsibility in enforcing regulations through annual on-site assessments as well as unannounced audits of manufacturing processes, subcontractors, and suppliers.
The number of notified bodies has decreased significantly due to the new designation requirements3. This will most likely impact manufacturers’ timelines for product certification as resources become more stretched.
Classification of medical devices is regulated by Annex VIII of the MDR. This classification system is based on the risk that the device poses to patient safety along with the following parameters:
Class III devices pose a high risk to patients. They are invasive and are intended to either support human life or prevent impairment of human health. Medical devices in this category require a conformity assessment by a notified body. Examples include pacemakers and prosthetic heart valves. Approximately 2% of devices in the EU market are Class III devices.
Class IIb devices pose a medium to high risk to patients. They are mostly invasive and may be installed in the body for more than 30 days. Medical devices in this category require a conformity assessment by a notified body. Examples include infusion pumps, ventilators, dialysis machines, and intensive care monitoring equipment. Approximately 8% of devices in the EU market are Class IIb devices.
Class IIa devices pose a medium risk to patients. They are typically invasive and are installed in the body for less than 30 days. Medical devices in this category require a conformity assessment by a notified body. Examples include hearing aids, ultrasonic diagnostic equipment, and catheters. Approximately 20% of medical devices in the EU market are Class IIa devices.
Class I devices are mostly noninvasive and pose a low risk to patients. Devices in this category are divided into the following subclasses:
Approximately 70% of devices in the EU market are Class I devices.
The route in which a device obtains its CE Mark (i.e., Annex IX, X, or XI) is determined by its classification.
Conformity assessment routes:
Under the MDR, the following medical devices have been reclassified to a higher risk category:
In addition to classification changes, the MDR (Annex XVI) has introduced new manufacturing and surveillance requirements for these previously unregulated devices:
Section 2: Key Changes Under New MDR
Economic Operator Roles and Responsibilities
Clinical Evaluations and Post-Market Clinical Follow-up (PMCF)
Post-Market Surveillance (PMS)
European Database for Medical Devices (EUDAMED)
Serious Incident and Corrective Action Reporting
Section 3: Quality Management System (QMS) Requirements
Section 4: Steps for a Successful EU MDR Implementation
Section 5: MDR Implementation Checklist
Section 7: Appendix - Frequently Asked Questions & MDR Quick Guide